Abivax ABVX

Abivax SA is a clinical stage biotechnology company that was incorporated under the laws of France on December 4 2013. The company’s registered office is located at 7 11 boulevard Haussmann 75009 Paris France. Abivax SA maintains a wholly owned subsidiary named Abivax LLC which was formed in Delaware on March 20 2023. The primary mission of Abivax SA is to discover and develop therapeutics that harness the body’s natural regulatory mechanisms to stabilize immune responses in chronic inflammatory diseases. The company’s initial focus is on inflammatory bowel disease which comprises ulcerative colitis and Crohn’s disease. Abivax SA’s lead drug candidate is obefazimod an oral small molecule that has been shown to increase the expression of a single microRNA referred to as miR 124. By enhancing miR 124 activity obefazimod aims to modulate several inflammatory pathways simultaneously while avoiding broad immunosuppression. In addition to obefazimod the company is pursuing a follow on compounds program designed to generate new molecules based on the same miR 124 platform. Abivax SA also conducts exploratory research into combination therapies that pair obefazimod with existing or investigational agents for inflammatory bowel disease.

We currently generate revenue from research collaborations licensing agreements and grant funding received from public and private sources. As a clinical stage company Abivax SA has not yet commercialized any product therefore there are no sales of approved medicines at this time. The company’s financial position was strengthened by the proceeds from its initial public offering on Euronext Paris and the concurrent Nasdaq ADS offering which raised approximately two hundred thirty five point eight million dollars in gross proceeds. These funds are being used to advance the Phase 3 ABTECT induction and maintenance trials of obefazimod for ulcerative colitis to support the ongoing Phase 2b trial in Crohn’s disease and to finance the follow on compounds program. In the future Abivax SA expects to receive milestone payments and royalties from any partnership or licensing arrangements that may be entered into as its pipeline progresses.

Abivax SA competes in the inflammatory bowel disease therapeutics arena against large established pharmaceutical companies such as AbbVie Johnson & Johnson Takeda Pfizer Eli Lilly and emerging biotech firms. The standard of care for ulcerative colitis and Crohn’s disease includes agents that target tumor necrosis factor alpha interleukin 12/23 integrin receptors interleukin 23 Janus kinase inhibitors sphingosine 1 p receptor agonists and experimental TL1A inhibitors. Many of these therapies are administered by injection or infusion and some carry boxed warnings concerning serious infections malignancy or cardiovascular events. Abivax SA’s lead candidate obefazimod differentiates itself by being an orally administered small molecule that works through the natural microRNA miR 124 pathway. This mechanism allows simultaneous influence on multiple cytokine pathways including tumor necrosis factor alpha interleukin 17 interleukin 6 and interferon gamma without causing generalized immune suppression. Clinical data from the Phase 3 ABTECT induction trials showed a placebo adjusted remission rate of sixteen point four percent for the fifty milligram dose and a comparable response across bio naïve and bio refractory patient subsets. The safety profile of obefazimod has been consistent with placebo showing no new safety signals up to ninety six weeks of exposure. The company’s intellectual property estate includes numerous patents covering the composition of matter synthesis methods and therapeutic uses of obefazimod with expiration dates extending into the late 2030s. These legal protections combined with the novel mechanism and oral dosing give Abivax SA a distinct competitive stance in a market dominated by injectable biologics.

The company’s future customers will be gastroenterologists hepatologists and other physicians who manage patients with ulcerative colitis and Crohn’s disease. Hospitals outpatient clinics and specialty infusion centers that provide care for inflammatory bowel disease represent the institutional settings where obefazimod would be dispensed if it receives regulatory approval. While the filing does not list specific named customers the addressable patient population consists of hundreds of thousands of individuals with moderate to severe ulcerative colitis and a similar number with moderate to severe Crohn’s disease primarily in the United States Europe and other developed markets. Abivax SA anticipates that prescribing physicians will value the oral dosing convenience and the favorable safety signal observed in clinical trials when deciding whether to include obefazimod in their treatment algorithms.